Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(midostaurin)
492 results
  • Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. [Review]
    Biomark Res 2019; 7:19Zhao J, Song Y, Liu D
  • FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) remains as one of the most frequently mutated genes in acute myeloid leukemia (AML), especially in those with normal cytogenetics. The FLT3-ITD and FLT3-TKD (tyrosine kinase domain) mutations are biomarkers for high risk AML and are associated with drug resistance and high risk of relapse. Multiple FLT3 inhibitors are in clinical …
  • Hematological malignancies and molecular targeting therapy. [Review]
    Eur J Pharmacol 2019; 862:172641Shimada A
  • Recent genetic analysis using next-generation sequencing (NGS) vastly improved the understanding of molecular mechanism of hematological malignancies. Many molecular targeting drugs have since been used in the clinic, which is timely as clinical outcomes using conventional chemotherapy and hematopoietic stem cell transplantation (HSCT) reached a plateau. The first memorable success in this field …
  • A personalized approach to acute myeloid leukemia therapy: current options. [Journal Article]
    Pharmgenomics Pers Med 2019; 12:167-179Illangeswaran RSS, Das S, … Balasubramanian P
  • Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic landscape and molecular etiology of AML. The approval of several novel drugs for targeted therapy, incl…
  • FLT3 inhibitor design using molecular docking based virtual screening for acute myeloid leukemia. [Journal Article]
    Bioinformation 2019; 15(2):104-115Gokhale P, Chauhan APS, … Singh SK
  • Acute Myeloid Leukaemia (AML) is a blood cancer, which affects the red blood cells in the bone marrow. Of the possible proteins that are affected in AML, fms-like tyrosine kinase 3 (FLT3) has long been recognized as a potential therapeutic target as it affects the other signaling pathways and leads to a cascade of events. First-generation inhibitors sorafenib and midostaurin, as well as secondgen…
  • Novel approaches to treating advanced systemic mastocytosis. [Review]
    Clin Pharmacol 2019; 11:77-92Gilreath JA, Tchertanov L, Deininger MW
  • Mastocytosis is a myeloproliferative neoplasm characterized by expansion of abnormal mast cells (MCs) in various tissues, including skin, bone marrow, gastrointestinal tract, liver, spleen, or lymph nodes. Subtypes include indolent systemic mastocytosis, smoldering systemic mastocytosis and advanced systemic mastocytosis (AdvSM), a term collectively used for the three most aggressive forms of the…
New Search Next